17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Targeting the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis and stemness via inhibition of KRAS/YAP1 signaling

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Vascular endothelial growth factor-C (VEGF-C) has been implicated in epithelial-mesenchymal transition (EMT) processes and various human cancers, including skin cancer. Skin cancer is an aggressive human malignancy with increasing incidence worldwide; however, the underlying mechanisms involved in VEGF-C-induced skin cancer stemness and metastasis remain unclear. Here, we report that VEGF-C enhances skin cancer migration, invasion and stemness through Slug up-regulation. Oncomine database analysis indicated that the KRAS/MAPK (mitogen-activated protein kinases) pathway and YAP1 (yes-associated protein 1) expression are positively correlated with metastatic skin cancer. We show that VEGF-C triggers the activation of KRAS/MAPK signaling to increase YAP1 and downstream Slug expression, which are suppressed by an anti-VEGFR3 (VEGF receptor 3) peptide, a specific peptide targeting VEGFR3. The VEGF-C-induced migration, invasion and stemness of skin cancer cells are also abrogated by the anti-VEGFR3 peptide. Based on these data, we reveal the role of the VEGF-C/VEGFR3-mediated KRAS/MAPK-YAP1/Slug pathway in skin cancer progression and propose that the VEGF-C/VEGFR3 axis is a promising target for the anti-VEGFR3 peptide.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          Molecular regulation of vessel maturation.

          The maturation of nascent vasculature, formed by vasculogenesis or angiogenesis, requires recruitment of mural cells, generation of an extracellular matrix and specialization of the vessel wall for structural support and regulation of vessel function. In addition, the vascular network must be organized so that all the parenchymal cells receive adequate nutrients. All of these processes are orchestrated by physical forces as well as by a constellation of ligands and receptors whose spatio-temporal patterns of expression and concentration are tightly regulated. Inappropriate levels of these physical forces or molecules produce an abnormal vasculature--a hallmark of various pathologies. Normalization of the abnormal vasculature can facilitate drug delivery to tumors and formation of a mature vasculature can help realize the promise of therapeutic angiogenesis and tissue engineering.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression.

            The dissemination of tumour cells is the prerequisite of metastases and is correlated with a loss of epithelial differentiation and the acquisition of a migratory phenotype, a hallmark of malignant tumour progression. A stepwise, irreversible accumulation of genetic alterations is considered to be the responsible driving force. But strikingly, metastases of most carcinomas recapitulate the organization of their primary tumours. Although current models explain distinct and important aspects of carcinogenesis, each alone can not explain the sum of the cellular changes apparent in human cancer progression. We suggest an extended, integrated model that is consistent with all aspects of human tumour progression - the 'migrating cancer stem (MCS)-cell' concept.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Oncogenic KRAS signalling in pancreatic cancer

              Pancreatic ductal adenocarcinoma (PDAC) is almost universally fatal. The annual number of deaths equals the number of newly diagnosed cases, despite maximal treatment. The overall 5-year survival rate of <5% has remained stubbornly unchanged over the last 30 years, despite tremendous efforts in preclinical and clinical science. There is unquestionably an urgent need to further improve our understanding of pancreatic cancer biology, treatment response and relapse, and to identify novel therapeutic targets. Rigorous research in the field has uncovered genetic aberrations that occur during PDAC development and progression. In most cases, PDAC is initiated by oncogenic mutant KRAS, which has been shown to drive pancreatic neoplasia. However, all attempts to target KRAS directly have failed in the clinic and KRAS is widely assumed to be undruggable. This has led to intense efforts to identify druggable critical downstream targets and nodes orchestrated by mutationally activated KRAS. This includes context-specific KRAS effector pathways, synthetic lethal interaction partners and KRAS-driven metabolic changes. Here, we review recent advances in oncogenic KRAS signalling and discuss how these might benefit PDAC treatment in the future.
                Bookmark

                Author and article information

                Journal
                Oncotarget
                Oncotarget
                Oncotarget
                ImpactJ
                Oncotarget
                Impact Journals LLC
                1949-2553
                17 January 2017
                25 November 2016
                : 8
                : 3
                : 5603-5618
                Affiliations
                1 Division of Dermatology, Tri-Service General Hospital Songshan Branch, National Defense Medical Center, Taipei 10581, Taiwan
                2 Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 11490, Taiwan
                3 Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 11490, Taiwan
                4 National Institute of Cancer Research, National Health Research Institutes, Zhunan, Miaoli County 35053, Taiwan
                5 Department of Biotechnology, Asia University, Taichung 41354, Taiwan
                6 Department of Periodontology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan
                7 Department of Dermatology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan
                8 Bioresource Collection and Research Center, Food Industry Research and Development Institute, Hsinchu 30062, Taiwan
                9 Institute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu 30013, Taiwan
                10 Graduate Institute of Biomedical Sciences, China Medical University, Taichung 40402, Taiwan
                11 Center for Molecular Medicine, China Medical University Hospital, Taichung 40447, Taiwan
                Author notes
                Correspondence to: Jen-Liang Su, jlsu@ 123456nhri.org.tw
                Article
                13629
                10.18632/oncotarget.13629
                5354933
                27901498
                76268e54-17de-4f9b-87a0-ff7dfc675bab
                Copyright: © 2017 Yeh et al.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 8 August 2016
                : 7 November 2016
                Categories
                Review

                Oncology & Radiotherapy
                vegf-c,yap1,metastasis,cancer stemness,skin cancer
                Oncology & Radiotherapy
                vegf-c, yap1, metastasis, cancer stemness, skin cancer

                Comments

                Comment on this article